[SCHEDULE 13G] Fresenius Medical Care AG Passive Investment Disclosure (>5%)
BlackRock reports 5% stake in Fresenius Medical Care
BlackRock, Inc. reports beneficial ownership of common stock of Fresenius Medical Care AG on Schedule 13G. BlackRock holds 13,447,914 shares, representing 5.00% of the outstanding common stock as of June 30, 2026.
BlackRock, Inc. reports beneficial ownership of common stock of Fresenius Medical Care AG on Schedule 13G. BlackRock holds 13,447,914 shares, representing 5.00% of the outstanding common stock as of June 30, 2026.
BlackRock has sole voting power over 12,463,277 shares and sole dispositive power over all 13,447,914 shares, with no shared voting or dispositive power. Various underlying clients may receive dividends or sale proceeds, but no single client exceeds five percent ownership of the class.
Positive
None.
Negative
None.
Key Figures
Shares beneficially owned:13,447,914 sharesPercent of class:5.00%Sole voting power:12,463,277 shares+5 more
8 metrics
Shares beneficially owned13,447,914 sharesCommon stock of Fresenius Medical Care AG beneficially owned by BlackRock
Percent of class5.00%Portion of Fresenius Medical Care AG common stock class held by BlackRock
Sole voting power12,463,277 sharesShares over which BlackRock has sole power to vote or direct the vote
Shared voting power0 sharesShares over which BlackRock has shared power to vote
Sole dispositive power13,447,914 sharesShares over which BlackRock has sole power to dispose or direct disposition
Shared dispositive power0 sharesShares over which BlackRock has shared dispositive power
Event date06/30/2026Date associated with the reported ownership position
Filing signature date07/28/2026Date signed by Managing Director Spencer Fleming
Key Terms
beneficially owned, sole voting power, sole dispositive power, Schedule 13G, +1 more
5 terms
beneficially ownedfinancial
"reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting powerfinancial
"Sole Voting Power 12,463,277.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerfinancial
"Sole Dispositive Power 13,447,914.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13Gregulatory
"this schedule has been filed on Schedule 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
percent of classfinancial
"Percent of class: 5.00 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in FMS does BlackRock report on this Schedule 13G?
BlackRock reports beneficial ownership of 13,447,914 Fresenius Medical Care AG common shares, representing 5.00% of the outstanding class as of June 30, 2026. This reflects holdings of certain BlackRock business units only.
How much voting power does BlackRock have in FMS according to this filing?
BlackRock has sole voting power over 12,463,277 Fresenius Medical Care AG common shares and no shared voting power. This defines how many shares BlackRock-controlled units can vote or direct the vote for.
What dispositive power over FMS shares does BlackRock disclose?
BlackRock reports sole dispositive power over 13,447,914 Fresenius Medical Care AG shares and no shared dispositive power. Sole dispositive power means BlackRock can decide how and when these shares are sold or otherwise disposed of.
Are any BlackRock clients individually above 5% ownership in FMS?
No. The filing states that while various persons may receive dividends or sale proceeds from Fresenius Medical Care AG shares managed by BlackRock, no one person’s interest exceeds five percent of the total outstanding common shares.
Who is the reporting person and where is it organized in this FMS Schedule 13G?
The reporting person is BlackRock, Inc., a corporation organized in Delaware. The principal business address given is 50 Hudson Yards, New York, NY 10001, and the filing aggregates certain of its business units.
What class of FMS securities and CUSIP are covered by this BlackRock filing?
The filing covers Common Stock of Fresenius Medical Care AG with CUSIP D2734Z107. These details identify the specific equity securities for which BlackRock is reporting beneficial ownership on Schedule 13G.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FRESENIUS MEDICAL CARE AG
(Name of Issuer)
Common Stock
(Title of Class of Securities)
D2734Z107
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
D2734Z107
1
Names of Reporting Persons
BlackRock, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
12,463,277.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
13,447,914.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
13,447,914.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.00 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
FRESENIUS MEDICAL CARE AG
(b)
Address of issuer's principal executive offices:
Else-Kroener-Strasse 1 Bad Homburg Germany 61346
Item 2.
(a)
Name of person filing:
BlackRock, Inc.
In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)
Address or principal business office or, if none, residence:
BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)
Citizenship:
See Item 4 of Cover Page
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
D2734Z107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
13447914
(b)
Percent of class:
5.00 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
12463277
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
13447914
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of FRESENIUS MEDICAL CARE AG. No one person's interest in the common stock of FRESENIUS MEDICAL CARE AG is more than five percent of the total outstanding common shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit 99
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.